DYRLEVA Trademark

Trademark Overview


On Friday, March 16, 2018, a trademark application was filed for DYRLEVA with the United States Patent and Trademark Office. The USPTO has given the DYRLEVA trademark a serial number of 87838100. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 1, 2021. This trademark is owned by Biohaven Pharmaceutical Holding CompanyLimited. The DYRLEVA trademark is filed in the Pharmaceutical Products category with the following description:

Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Scler...
dyrleva

General Information


Serial Number87838100
Word MarkDYRLEVA
Filing DateFriday, March 16, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 1, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 31, 2018

Trademark Statements


Goods and ServicesMedicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use; all of the foregoing specifically excluding medicated and pharmaceutical preparations and substances for the treatment or management of respiratory diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 23, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBiohaven Pharmaceutical Holding CompanyLimited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressNew Haven, CT 06510

Party NameBiohaven Pharmaceutical Holding CompanyLimited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressNew Haven, CT 06510

Trademark Events


Event DateEvent Description
Monday, November 1, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 1, 2021ABANDONMENT - NO USE STATEMENT FILED
Thursday, April 22, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 21, 2021EXTENSION 5 GRANTED
Tuesday, March 23, 2021EXTENSION 5 FILED
Tuesday, March 23, 2021TEAS EXTENSION RECEIVED
Thursday, September 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 15, 2020EXTENSION 4 GRANTED
Tuesday, September 15, 2020EXTENSION 4 FILED
Tuesday, September 15, 2020TEAS EXTENSION RECEIVED
Wednesday, March 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 2, 2020EXTENSION 3 GRANTED
Monday, March 2, 2020EXTENSION 3 FILED
Monday, March 2, 2020TEAS EXTENSION RECEIVED
Wednesday, October 23, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, October 23, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, September 14, 2019EXTENSION 2 GRANTED
Saturday, September 14, 2019EXTENSION 2 FILED
Saturday, September 14, 2019TEAS EXTENSION RECEIVED
Tuesday, April 2, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, April 1, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, March 14, 2019TEAS POST PUBLICATION AMENDMENT RECEIVED
Friday, March 8, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 6, 2019EXTENSION 1 GRANTED
Wednesday, March 6, 2019EXTENSION 1 FILED
Wednesday, March 6, 2019TEAS EXTENSION RECEIVED
Tuesday, September 25, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 31, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 31, 2018PUBLISHED FOR OPPOSITION
Wednesday, July 11, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 27, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 26, 2018ASSIGNED TO EXAMINER
Friday, March 23, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, March 20, 2018NEW APPLICATION ENTERED IN TRAM